bioMerieux SA

BIM

Equity

ISIN FR0013280286 / Valor 38147803

Euronext - Euronext Paris (2024-09-18)

EUR 107.30-0.19%

bioMerieux SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

bioMérieux SA is a global leader in the field of in vitro diagnostics, providing a wide range of diagnostic solutions to healthcare providers. The company specializes in the development, production, and marketing of diagnostic systems and services that are used in clinical applications. Among its innovative offerings, bioMérieux provides the VIDAS® KUBE™, an advanced automated immunoassay solution that enhances laboratory operations with its flexibility and cost-effectiveness. Additionally, the company offers SPOTFIRE®, a multiplex PCR solution tailored for point-of-care testing that delivers rapid, onsite actionable results, and VITEK® MS PRIME, which leverages mass spectrometry technology to improve daily laboratory workflows and patient care, particularly in the critical area of sepsis management. bioMérieux's commitment to advancing healthcare is evident in its comprehensive approach to sepsis management, offering solutions that support the entire process from antibiotic initiation through to appropriate discontinuation. Through its focus on innovation and efficiency, bioMérieux SA plays a crucial role in enhancing diagnostic capabilities and improving patient outcomes worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Income

bioMérieux SA reported a contributive operating income of €610 million for the fourth quarter of 2023, representing 16.6% of sales. This marks a 2% increase at constant exchange rates and scope, despite facing higher-than-expected negative forex exchange headwinds amounting to -€55 million.

Operating Income

The Group's operating income for the fourth quarter of 2023 was €439 million, a decrease of 25% compared to €587 million in 2022. This decline was primarily due to the amortization and impairment of acquisition-related intangible assets, which amounted to €171 million, up from €77 million in 2022.

Net Income

bioMérieux SA's net income, Group share, reached €358 million in the fourth quarter of 2023, down from €452 million in 2022. The effective tax rate for the period stood at 26.2%, compared to 24.1% in 2022, mainly due to the impact of the Hybiome impairment.

Cash Management

Free cash flow for bioMérieux SA in the fourth quarter of 2023 was €115 million, down from €195 million in 2022. This decrease was influenced by a rise in working capital requirements, primarily due to an increase in inventories by €193 million, and capital expenditures amounting to €338 million, up from €287 million in 2022.

Dividend

The Board of Directors of bioMérieux SA recommended a stable dividend of €0.85 per share for the fourth quarter of 2023, representing a payout ratio of 28% of net income, Group share. This recommendation will be presented for approval at the Annual General Meeting on May 23, 2024.

Summarized from source with an LLMView Source

Key figures

17.4%1Y

-6.37%3Y

48.4%5Y

Performance

22.8%1Y

27.9%3Y

31.9%5Y

Volatility